Our findings suggest that targeting the HK3/EP300/TFAP2A axis could be a potential therapeutic strategy to enhance the efficacy of PD-L1-mediated immune checkpoint blockade therapy for ccRCC patients. The gene discussed is HK3; the disease is nonpapillary renal cell carcinoma.